Novavax and the European Commission have finalised an advance buy settlement for up to 200 million doses of Covid-19 vaccines.
The preliminary transaction will contain 100 million doses of the brand new NVX-CoV2373 vaccine, however there would be the possibility for a further 100 million doses by way of 2023.
This is a recombinant nanoparticle protein-based Covid-19 vaccine.
The biotechnology firm is at present working to full its rolling submission for this kind of vaccine to the European Medicines Agency within the third quarter of 2021, with supply of preliminary doses anticipated to start following approval.
President and CEO of Novavax Stanley C. Erck stated: "We thank the European Commission for their partnership on this vital step to increase vaccine choices for the residents of Europe and globally as we work to carry the primary Covid-19 protein subunit vaccine to the market.
"With clinical data from our trials showing strong efficacy against variants of concern and variants of interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world."
based mostly on website supplies www.rte.ie